Effect of Immersive Virtual Reality With Multisensory Stimulation on the Functional Impact of Hemineglect Secondary to a Right-Sided Stroke

Launched by HOPITAL LA MUSSE · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of an innovative virtual reality program, called the VirtySens® capsule, on patients who have experienced a right-sided stroke and are dealing with a cognitive condition known as hemineglect. Hemineglect makes it difficult for individuals to notice or respond to things on one side of their body, which can significantly impact their daily life and independence. The trial aims to see if this immersive virtual reality experience, which stimulates multiple senses like sight, sound, smell, and touch, can help reduce the challenges caused by hemineglect in patients who have had a stroke within the last three months.

To participate in this trial, individuals must be over 18 years old and have had their first right-sided ischemic stroke confirmed by a doctor. They should also be diagnosed with left hemineglect and have normal or corrected vision. Participants will undergo evaluations and rehabilitation sessions at La Musse Hospital, where an occupational therapist will assess their condition and provide tailored support. Each participant can expect weekly evaluations for 10 to 12 weeks and three rehabilitation sessions each week for five weeks. This study is currently not recruiting participants, but it highlights a new approach to improving recovery after a stroke.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient aged over 18 years
• • Diagnosis of first ischemic right stroke established by a neurologist using clinical examination and brain imaging (CT scan or MRI)
• • Stroke occurring less than 3 months ago
• • Presence of left hemineglect, diagnosed using the Neglect Assessment Battery (NAB)
• • Normal vision or corrected to normal
• • Patient affiliated with the social security system
• Exclusion Criteria:
• • History of neurological or psychiatric illness
• • Epilepsy
• • Craniotomy
• • Limited range of cervical motion due to orthopedic disorders
• • Moderate or severe deafness (hearing loss of 40 dB in one ear, as measured by tonal audiometry)
• • Anosmia (loss of smell)
• • Asthmatic disease
• • Pregnant women or women suspected of being pregnant
• • Breastfeeding women
• • Severe neurocognitive disorders with an MMSE score \< 21
• • Patient under legal protection measures
• • Minor patient
• • Patient enrolled in another research protocol